Cystadenoma
Cystadenoma, Mucinous
Cystadenoma, Serous
Cystadenocarcinoma
Mucocele
Biliary Tract Neoplasms
Cysts
Sertoli-Leydig Cell Tumor
Bile Ducts, Intrahepatic
Pancreatic Neoplasms
Adenolymphoma
Cystadenocarcinoma, Mucinous
Hepatic Duct, Common
Spermatocele
Ovarian Neoplasms
Aspermia
Pseudomyxoma Peritonei
Pancreatic Cyst
Neoplasms, Multiple Primary
Salivary Glands, Minor
Tomography, X-Ray Computed
Pancreatic Pseudocyst
Cholangiopancreatography, Magnetic Resonance
Bile Ducts, Extrahepatic
Cystadenocarcinoma, Serous
Epithelial thyroid tumors in cows. (1/197)
From 1964 to 1973, 370 tumors were collected from cows of unknown age. Ten (2.7%) of these were primary thyroid tumors. Three were malignant. The benign tumors were solitary encapsulated adenomas in the parenchyma with more or less defined trabeculae, tubular, and microfollicular pattern. One of the malignant tumors was a cystic papillary adenocarcinoma, and two were small cell carcinomas consisting of small, sometimes binuclear, pleomorphic cells. (+info)Vascular endothelial growth factor levels in ovarian cyst fluid correlate with malignancy. (2/197)
Ovarian cancer is a richly vascularized neoplasm with solid and cystic components. The purpose of this study was to determine whether cyst fluid could be used to quantitatively evaluate production of angiogenic factors in ovarian lesions. ELISA was used to measure vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in the cyst fluid of patients with ovarian cancer (n = 13), benign cysts and cystadenomas (n = 23), borderline tumors (n = 5), and functional cysts (n = 8). VEGF levels were markedly elevated in the fluid of malignant cysts (38.5+/-8.2 ng/ml) as compared with benign (1.6+/-0.4 ng/ml; P < 0.001), borderline (5.7+/-1.5 ng/ml; P < 0.001), or functional cysts (3.8+/-2.0 ng/ml; P < 0.001). The presence of VEGF in cancer cells was confirmed by immunohistochemistry. Follow-up of patients with malignant and borderline lesions demonstrated a correlation between VEGF levels in cyst fluid and tumor recurrence (P = 0.03). bFGF in malignant cysts was either undetectable or very low (0.3+/-0.2 ng/ml), and no significant differences were found in bFGF levels among malignant, benign, borderline, and functional cysts. This study demonstrates that ovarian malignancy is associated with dramatic elevation of VEGF levels in ovarian cyst fluid. Conversely, there is no correlation between cyst fluid bFGF levels and malignant transformation. The high levels of VEGF in malignant cysts are consistent with the hypothesis that this growth factor plays an important role in ovarian cancer related-angiogenesis and tumor progression and represents a potentially important target of antiangiogenic therapy. (+info)Mucin Hypersecreting Intraductal Papillary Neoplasm of the pancreas. (3/197)
Mucin Hypersecreting Intraductal Papillary Neoplasm is a rare neoplasm that arises from ductal epithelial cells. This entity is distinct from the more commonly known Mucinous Cystadenoma or Mucinous Cystadenocarcinoma. Despite this distinction, it has been erroneously categorized with these more common cystic neoplasms. Characteristic clinical presentation, radiographic, and endoscopic findings help distinguish this neoplasm from the cystadenomas and cystadenocarcinomas. Histopathologic identification is not crucial to the preoperative diagnosis. This neoplasm is considered to represent a premalignant condition and, therefore, surgical resection is warranted. Prognosis, following resection, is felt to be curative for the majority of patients. We present two cases of Mucin Hypersecreting Intraductal Papillary Neoplasm and discuss their diagnosis and surgical therapy. (+info)Tsc2(+/-) mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background. (4/197)
Tuberous sclerosis (TSC) is an autosomal dominant genetic disorder in which benign hamartomas develop in multiple organs, caused by mutations in either TSC1 or TSC2. We developed a murine model of Tsc2 disease using a gene targeting approach. Tsc2-null embryos die at embryonic days 9.5-12.5 from hepatic hypoplasia. Tsc2 heterozygotes display 100% incidence of multiple bilateral renal cystadenomas, 50% incidence of liver hemangiomas, and 32% incidence of lung adenomas by 15 months of age. Progression to renal carcinoma, fatal bleeding from the liver hemangiomas, and extremity angiosarcomas all occur at a rate of less than 10%. The renal cystadenomas develop from intercalated cells of the cortical collecting duct and uniformly express gelsolin at high levels, enabling detection of early neoplastic lesions. The tumor expression pattern of the mice is influenced by genetic background, with fewer large renal cystadenomas in the outbred Black Swiss background and more angiosarcomas in 129/SvJae chimeric mice. The slow growth of the tumors in the heterozygote mice matches the limited growth potential of the great majority of TSC hamartomas, and the influence of genetic background on phenotype correlates with the marked variability in expression of TSC seen in patients. (+info)Alterations in the expression of the DNA repair/redox enzyme APE/ref-1 in epithelial ovarian cancers. (5/197)
The DNA base excision repair pathway is responsible for the repair of alkylation and oxidative DNA damage. A crucial step in the base excision repair pathway involves the cleavage of an apurinic/apyrimidinic (AP) site in DNA by an AP endonuclease (APE). The major AP endonuclease in mammalian cells is APE/ref-1, a multifunctional enzyme that acts not only as an AP endonuclease but as a redox-modifying factor for a variety of transcription factors. The purpose of this study was to determine the expression of APE/redox factor-1 (ref-1) in ovarian tissues, particularly ovarian cancers. Formalin-fixed, paraffin-embedded specimens of ovarian tissues (normal, various benign conditions, and epithelial cancers) were studied using both polyclonal and monoclonal antibodies to APE/ref-1. The relationship between APE/ref-1 protein levels and DNA repair activity was studied in ovarian Hey and Hey-C2 cell lines using Western blot and a specific AP-site oligonucleotide cleavage assay. Hey and Hey-C2 cells were fractionated, and the nuclear and cytoplasmic extracts were quantitated for protein levels and assessed for APE/ref-1 with Western blot. Normal ovarian tissues consistently demonstrated strong nuclear staining of the surface epithelium, epithelial inclusions, corpora lutea and albicantia, and stroma. Cytoplasmic staining was absent. A similar pattern was seen for benign conditions including endometriosis. Low malignant potential ovarian cancers stained in a pattern similar to normal ovarian and nonneoplastic tissues; however, two specimens also had areas of cytoplasmic staining. Epithelial ovarian cancers were remarkably different from all other ovarian tissues studied. Both nuclear and cytoplasmic staining of the malignant epithelium were seen and ranged from strong to weak, often with considerable staining heterogeneity within the same tumor. The AP-site oligonucleotide cleavage assay indicated that APE/ref-1 protein levels correlate well with DNA repair activity. The increased levels of APE/ref-1 in the Hey-C2 cells was mainly attributable to increased cytoplasmic enzyme. APE/ref-1 immunoreactivity is altered in malignant ovarian tumors. Further studies will determine whether the altered expression and subcellular location reflect changes in redox regulatory functions. (+info)Accumulation of collagen in ovarian benign tumours. (6/197)
Extracellular matrix components of benign ovarian tumours (cystadenoma, adenofibroma, cystadenofibroma) were analysed. The investigated tumours contained twice as much collagen than control ovarian tissues. Significant alterations in mutual quantitative relationships between collagens of various types were observed. The proportion of type I collagen decreased and that of type III collagen increased. The accumulation of collagen was accompanied by a reduction in sulphated glycosaminoglycan content whereas the amount of hyaluronic acid was not changed. Dermatan sulphate was the most abundant glycosaminoglycan component. It is suggested that the accumulation of collagen (natural barrier to the migration of tumour cells) and underexpression of glycosaminoglycans/proteoglycans (binding some growth factors and interleukins) may exert an inhibitory effect on tumour growth. (+info)Contrast-enhanced sonography in the examination of benign and malignant adnexal masses. (7/197)
Our objective was to characterize the properties of an intravascular ultrasonographic contrast agent in examination of adnexal masses and to compare contrast agent properties between benign and malignant adnexal tumors. Fifty-eight consecutively examined women with suspected ovarian tumors were examined preoperatively by power Doppler ultrasonography, first without and then with contrast agent enhancement (Levovist). Fourteen women had ovarian cancer, 3 had borderline ovarian tumors, 18 had benign ovarian neoplasms, and 23 had functional adnexal cystic masses or endometriomas. The effect of the contrast agent was evaluated visually and by using computerized power Doppler signal intensity measurements. In visual evaluation, the brightness of the power Doppler signal and the amount of recognizable vascular areas increased in each tumor after contrast agent administration. The number of vessels in power Doppler ultrasonograms, both before and after contrast agent enhancement, was significantly higher in malignant than in benign adnexal masses, as also was the increase in the number of recognizable vessels after contrast agent administration. Contrast agent uptake time was significantly shorter in malignant than in benign tumors. No significant differences were found in the power Doppler signal intensities or their changes between benign and malignant tumors. In conclusion, use of sonographic contrast agent facilitates imaging of tumor vessels. For differentiation of benign and malignant tumors, the kinetic properties of the contrast agent, such as uptake and washout times, may have more potential than the use of the contrast agent in anatomic imaging of the tumor vessels. (+info)Molecular characterization of pancreatic serous microcystic adenomas: evidence for a tumor suppressor gene on chromosome 10q. (8/197)
Pancreatic serous microcystic adenomas (SCAs) are rare, benign tumors with a striking female preference. Virtually no information is available about chromosomal or genetic anomalies in this disease. We performed extensive molecular characterization of 21 cases of formalin-fixed, paraffin-embedded sporadic SCAs consisting in genome-wide allelic loss analysis with 79 microsatellite markers covering all 22 autosomes, assessment of microsatellite instability, and mutational analysis of the VHL, K-ras, and p53 genes in nine cases for which frozen tissue was available. Although no case showed microsatellite instability of the type seen in mismatch repair-deficient tumors, a relatively low fractional allelic loss of 0.08 was found. Losses on chromosome 10q were the most frequent event in SCAs (50% of cases), followed by allelic losses on chromosome 3p (40% of cases). Moderately frequent losses (>25% of cases) were found on chromosomes 1q, 2q, and 7q. The VHL gene, located on chromosome 3p, had somatic inactivating mutations in two of nine cases (22%), whereas no mutations were found in either K-ras or p53, in agreement with the finding that all 21 cases stained negative for p53 by immunohistochemistry. Our study indicates that the involvement of chromosomal arms 10q and 3p is characteristic of SCAs and that the VHL gene is involved in a subset of sporadic cases. (+info)Note: The above definition is intended to provide a general understanding of the term 'Cystadenoma' and should not be considered as medical advice or diagnosis. If you have any concerns about your health, please consult a qualified medical professional for proper evaluation and care.
Characteristics:
* Mucinous cystadenomas are typically slow-growing and asymptomatic, but can occasionally cause pelvic pain or discomfort due to their size.
* They are usually unilateral (affecting one ovary), but can rarely occur bilaterally (affecting both ovaries).
* The tumor is composed of mucin-secreting epithelial cells that form glands or cysts within a fibrous stroma.
* Cystadenomas are typically encapsulated, but can rarely become invasive and infiltrate surrounding tissues.
* Mucinous cystadenomas are usually small (less than 5 cm in diameter), but can occasionally be larger.
Diagnosis:
* Imaging studies such as ultrasound or computed tomography (CT) scans may be used to detect the presence of a cystic mass in the ovary, but a definitive diagnosis is usually made through surgical exploration and histopathologic examination of the tumor tissue.
* A preoperative diagnosis of mucinous cystadenoma can be challenging, as the imaging features are not specific and may resemble other ovarian tumors, such as serous cystadenomas or borderline tumors.
Treatment:
* Surgical excision is the primary treatment for mucinous cystadenoma, and the procedure is usually performed through a laparotomy or laparoscopy.
* The surgical approach depends on the size and location of the tumor, as well as the patient's age and fertility status.
* In some cases, the tumor may be removed through a staged approach, with initial cytoreduction followed by chemotherapy or radiation therapy to shrink the remaining tumor burden.
Prognosis:
* Mucinous cystadenoma is generally considered a benign tumor, and the prognosis is excellent for most patients.
* The overall survival rate is high, and the majority of patients can expect to be cured with surgical excision alone.
* However, in rare cases, mucinous cystadenoma can recur or progress to more aggressive types of ovarian cancer, such as serous carcinoma.
Follow-up:
* After surgical excision, patients with mucinous cystadenoma should be followed up with regular pelvic examinations, imaging studies, and serum CA 125 levels to monitor for any signs of recurrence or progression.
* The frequency of follow-up appointments may vary depending on the patient's age, tumor size, and other factors, but annual pelvic examinations and imaging studies are generally recommended for at least 5 years after surgery.
References:
1. Kurman RJ, et al. The origin and pathology of ovarian borderline tumors. International Journal of Gynecological Pathology. 2014;33(2):197-211.
2. Di Cerbo A, et al. Mucinous cystadenoma of the ovary: a review of the literature. Journal of Obstetrics and Gynaecology Canada. 2018;40(6):753-763.
3. Chung H, et al. The clinicopathological features and prognosis of mucinous cystadenoma of the ovary: a systematic review and meta-analysis. Gynecologic Oncology Reports. 2018;20:135-143.
The term "cystadenoma" refers to a benign tumor that grows from glandular tissue, and "serous" indicates that the tumor is derived from the serous (fluid-producing) cells of the ovary. The tumor typically forms a cystic mass filled with a clear or cloudy liquid, and can range in size from small to several centimeters in diameter.
CS usually affects women during their reproductive years, and the peak incidence is between 20 and 40 years of age. Symptoms may include abdominal pain, bloating, and vaginal bleeding, but many cases are asymptomatic and are detected incidentally during pelvic examination or imaging studies.
The exact cause of CS is not known, but it is believed to be related to genetic mutations and hormonal factors. The tumor cells have a characteristic immunophenotype, with expression of markers such as cytokeratin 7 and epidermal growth factor receptor (EGFR).
The diagnosis of CS is based on a combination of imaging studies, such as ultrasound and computed tomography (CT), and histopathological examination of tissue samples obtained through laparoscopy or surgery. Treatment options for CS include watchful waiting, fertility-sparing surgery, and total hysterectomy with bilateral salpingo-oophorectomy (THBSO).
In summary, cystadenoma, serous is a common type of benign ovarian tumor that originates from the serous cells of the ovary. It typically affects women during their reproductive years and can cause symptoms such as abdominal pain and vaginal bleeding. The exact cause is not known, but it is believed to be related to genetic mutations and hormonal factors. Diagnosis is based on a combination of imaging studies and histopathological examination of tissue samples, and treatment options include watchful waiting, fertility-sparing surgery, and total hysterectomy with bilateral salpingo-oophorectomy.
Example sentence: "After undergoing surgery to remove the papillary cystadenoma, the patient made a full recovery."
Cystadenocarcinoma can occur in various parts of the body, but it is most common in the ovary and breast. In the ovary, it is the most common type of ovarian cancer and accounts for about 70% of all ovarian cancers. In the breast, it is a rare type of breast cancer, accounting for less than 5% of all breast cancers.
The symptoms of cystadenocarcinoma can vary depending on the location of the tumor, but they may include:
* Abnormal vaginal bleeding or discharge
* Pelvic pain or discomfort
* Abdominal swelling or bloating
* Painful urination
* Weakness and fatigue
Cystadenocarcinoma is diagnosed through a combination of imaging tests, such as ultrasound, CT scan, or MRI, and biopsy. Treatment options may include surgery, chemotherapy, and/or radiation therapy, depending on the stage and location of the cancer.
The prognosis for cystadenocarcinoma depends on the stage of the cancer at the time of diagnosis. In general, early detection and treatment improve the chances of a successful outcome. However, cystadenocarcinoma can be an aggressive cancer, and the 5-year survival rate is lower for advanced stages of the disease.
In summary, cystadenocarcinoma is a type of cancer that arises from glandular cells in various parts of the body, but most commonly in the ovary and breast. It can cause a range of symptoms and is diagnosed through imaging tests and biopsy. Treatment options include surgery, chemotherapy, and/or radiation therapy, and the prognosis depends on the stage of the cancer at the time of diagnosis.
Appendiceal neoplasms refer to abnormal growths or tumors that occur in the appendix, a small tube-like structure attached to the large intestine. These growths can be benign (non-cancerous) or malignant (cancerous). Malignant appendiceal neoplasms are rare, but they can spread quickly to other parts of the body if left untreated.
Types of Appendiceal Neoplasms:
There are several types of appendiceal neoplasms, including:
1. Adenoma: A benign tumor that arises from glandular cells in the appendix.
2. Carcinoma: A malignant tumor that arises from epithelial cells in the appendix.
3. Mucinous cystadenoma: A benign tumor that arises from glandular cells in the appendix and typically contains mucin, a type of protein.
4. Goblet cell carcinoid: A rare type of malignant tumor that arises from goblet cells, which are specialized cells that produce mucin in the appendix.
5. Signet ring cell carcinoma: A rare and aggressive type of malignant tumor that arises from glandular cells in the appendix.
Symptoms and Diagnosis:
The symptoms of appendiceal neoplasms can vary depending on the size and location of the tumor, but may include abdominal pain, nausea, vomiting, fever, and loss of appetite. Diagnosis is typically made through a combination of physical examination, imaging tests such as CT scans or MRI, and biopsy.
Treatment:
Treatment for appendiceal neoplasms usually involves surgical removal of the affected appendix, which may involve a laparoscopic or open procedure. In some cases, chemotherapy or radiation therapy may also be recommended to destroy any remaining cancer cells. The prognosis for patients with appendiceal neoplasms depends on the type and stage of the tumor at the time of diagnosis.
Prognosis:
The prognosis for patients with appendiceal neoplasms is generally good if the tumor is detected early and treated appropriately. However, if the tumor is not diagnosed until a later stage, the prognosis may be poorer. The 5-year survival rate for patients with appendiceal cancer is approximately 70-80%.
Conclusion:
Appendiceal neoplasms are rare and aggressive tumors that can arise in the appendix. Early diagnosis and treatment are critical for improving outcomes. Imaging tests such as CT scans and MRI can help identify these tumors, and surgical removal of the affected appendix is usually the first line of treatment. Chemotherapy or radiation therapy may also be recommended in some cases. The prognosis for patients with appendiceal neoplasms is generally good if the tumor is detected early, but can be poorer if not diagnosed until a later stage.
A mucocele is a type of benign growth that occurs on the mucous membranes, such as those found in the mouth, nose, or throat. It is a soft, painless tumor that is typically filled with mucus. Mucoceles are usually small and can be either pedunculated (attached to the surrounding tissue by a stalk) or exophytic (growing outward from the surface of the mucous membrane).
Synonyms: mucous cyst, mucinous cyst, mucous tumor, benign mucosal tumor.
Etymology: From Latin muco- (mucus) + cele (cyst, sac).
Examples of Mucocele in a sentence:
1. The patient presented with a painless mucocele on her lower lip that had been present for several months.
2. The otolaryngologist removed the mucocele from the patient's nasal cavity using a surgical shaver.
3. The pathology report confirmed that the growth was a benign mucocele and not a malignancy.
Biliary tract neoplasms refer to abnormal growths or tumors that occur in the biliary tract, which includes the liver, gallbladder, and bile ducts. These tumors can be benign (non-cancerous) or malignant (cancerous).
There are several types of biliary tract neoplasms, including:
1. Cholangiocarcinoma: This is a rare type of cancer that originates in the cells lining the bile ducts. It can occur in the liver or outside the liver.
2. Gallbladder cancer: This type of cancer occurs in the gallbladder and is relatively rare.
3. Hepatocellular carcinoma (HCC): This is the most common type of primary liver cancer, which means it originates in the liver rather than spreading from another part of the body.
4. Bile duct cancer: This type of cancer occurs in the bile ducts that carry bile from the liver and gallbladder to the small intestine.
Biliary tract neoplasms can cause a variety of symptoms, including abdominal pain, jaundice (yellowing of the skin and eyes), weight loss, fatigue, and itching. These symptoms can be non-specific and may resemble those of other conditions, making diagnosis challenging.
Diagnosis of biliary tract neoplasms usually involves a combination of imaging tests such as ultrasound, CT scans, MRI, and PET scans, as well as biopsies to confirm the presence of cancer cells. Treatment options for biliary tract neoplasms depend on the type, size, location, and stage of the tumor, and may include surgery, chemotherapy, radiation therapy, or a combination of these.
Bile duct neoplasms refer to abnormal growths or tumors that occur in the bile ducts, which are the tubes that carry bile from the liver and gallbladder to the small intestine. Bile duct neoplasms can be benign (non-cancerous) or malignant (cancerous).
Types of Bile Duct Neoplasms:
There are several types of bile duct neoplasms, including:
1. Bile duct adenoma: A benign tumor that grows in the bile ducts.
2. Bile duct carcinoma: A malignant tumor that grows in the bile ducts and can spread to other parts of the body.
3. Cholangiocarcinoma: A rare type of bile duct cancer that originates in the cells lining the bile ducts.
4. Gallbladder cancer: A type of cancer that occurs in the gallbladder, which is a small organ located under the liver that stores bile.
Causes and Risk Factors:
The exact cause of bile duct neoplasms is not known, but there are several risk factors that may increase the likelihood of developing these tumors, including:
1. Age: Bile duct neoplasms are more common in people over the age of 50.
2. Gender: Women are more likely to develop bile duct neoplasms than men.
3. Family history: People with a family history of bile duct cancer or other liver diseases may be at increased risk.
4. Previous exposure to certain chemicals: Exposure to certain chemicals, such as thorium, has been linked to an increased risk of developing bile duct neoplasms.
Symptoms:
The symptoms of bile duct neoplasms can vary depending on the location and size of the tumor. Some common symptoms include:
1. Yellowing of the skin and eyes (jaundice)
2. Fatigue
3. Loss of appetite
4. Nausea and vomiting
5. Abdominal pain or discomfort
6. Weight loss
7. Itching all over the body
8. Dark urine
9. Pale stools
Diagnosis:
Diagnosis of bile duct neoplasms typically involves a combination of imaging tests and biopsy. The following tests may be used to diagnose bile duct neoplasms:
1. Ultrasound: This non-invasive test uses high-frequency sound waves to create images of the liver and bile ducts.
2. Computed tomography (CT) scan: This imaging test uses X-rays and computer technology to create detailed images of the liver and bile ducts.
3. Magnetic resonance imaging (MRI): This test uses a strong magnetic field and radio waves to create detailed images of the liver and bile ducts.
4. Endoscopic ultrasound: This test involves inserting an endoscope (a thin, flexible tube with a small ultrasound probe) into the bile ducts through the mouth or stomach to obtain images and samples of the bile ducts.
5. Biopsy: A biopsy may be performed during an endoscopic ultrasound or during surgery to remove the tumor. The sample is then examined under a microscope for cancer cells.
Treatment:
The treatment of bile duct neoplasms depends on several factors, including the type and stage of the cancer, the patient's overall health, and the patient's preferences. The following are some common treatment options for bile duct neoplasms:
1. Surgery: Surgery may be performed to remove the tumor or a portion of the bile duct. This may involve a Whipple procedure (a surgical procedure to remove the head of the pancreas, the gallbladder, and a portion of the bile duct), a bile duct resection, or a liver transplant.
2. Chemotherapy: Chemotherapy may be used before or after surgery to shrink the tumor and kill any remaining cancer cells.
3. Radiation therapy: Radiation therapy may be used to destroy cancer cells that cannot be removed by surgery or to relieve symptoms such as pain or blockage of the bile duct.
4. Stent placement: A stent may be placed in the bile duct to help keep it open and improve blood flow to the liver.
5. Ablation therapy: Ablation therapy may be used to destroy cancer cells by freezing or heating them with a probe inserted through an endoscope.
6. Targeted therapy: Targeted therapy may be used to treat certain types of bile duct cancer, such as cholangiocarcinoma, by targeting specific molecules that promote the growth and spread of the cancer cells.
7. Clinical trials: Clinical trials are research studies that evaluate new treatments for bile duct neoplasms. These may be an option for patients who have not responded to other treatments or who have advanced cancer.
Prevalence: Adenomas account for approximately 10% to 20% of all primary liver tumors.
Risk Factors: Risk factors for developing adenoma include age (>60 years old), cirrhosis, and a family history of hepatocellular carcinoma or polycystic liver disease.
Pathology: Adenomas are typically slow-growing and may not cause symptoms in the early stages. They can grow large enough to obstruct bile flow and cause abdominal pain, jaundice, and pruritus.
Diagnosis: Adenomas are diagnosed via imaging studies such as ultrasound, computed tomography (CT), or magnetic resonance imaging (MRI). Endoscopic ultrasound may also be used to evaluate the tumor and assess for invasive features.
Treatment: Surgical resection is the primary treatment for adenomas. In some cases, liver transplantation may be considered if the tumor is large or multiple and surgical resection is not feasible. Ablation therapies such as radiofrequency ablation or chemoembolization may also be used to control symptoms and slow tumor growth.
Prognosis: The prognosis for patients with adenoma is generally good, with a 5-year survival rate of approximately 90%. However, the risk of malignant transformation (cancer) is present, particularly in cases where there are multiple adenomas or invasive features.
In conclusion, adenoma of the bile ducts is a benign tumor that can occur within the liver. While the prognosis is generally good, early detection and treatment are important to prevent complications and minimize the risk of malignant transformation.
There are many different types of cysts that can occur in the body, including:
1. Sebaceous cysts: These are small, usually painless cysts that form in the skin, particularly on the face, neck, or torso. They are filled with a thick, cheesy material and can become inflamed or infected.
2. Ovarian cysts: These are fluid-filled sacs that form on the ovaries. They are common in women of childbearing age and can cause pelvic pain, bloating, and other symptoms.
3. Kidney cysts: These are fluid-filled sacs that form in the kidneys. They are usually benign but can cause problems if they become large or infected.
4. Dermoid cysts: These are small, usually painless cysts that form in the skin or organs. They are filled with skin cells, hair follicles, and other tissue and can become inflamed or infected.
5. Pilar cysts: These are small, usually painless cysts that form on the scalp. They are filled with a thick, cheesy material and can become inflamed or infected.
6. Epidermoid cysts: These are small, usually painless cysts that form just under the skin. They are filled with a thick, cheesy material and can become inflamed or infected.
7. Mucous cysts: These are small, usually painless cysts that form on the fingers or toes. They are filled with a clear, sticky fluid and can become inflamed or infected.
8. Baker's cyst: This is a fluid-filled cyst that forms behind the knee. It can cause swelling and pain in the knee and is more common in women than men.
9. Tarlov cysts: These are small, fluid-filled cysts that form in the spine. They can cause back pain and other symptoms, such as sciatica.
10. ganglion cysts: These are noncancerous lumps that form on the joints or tendons. They are filled with a thick, clear fluid and can cause pain, swelling, and limited mobility.
It's important to note that this is not an exhaustive list and there may be other types of cysts that are not included here. If you suspect that you have a cyst, it's always best to consult with a healthcare professional for proper diagnosis and treatment.
Sertoli-Leydig cell tumors account for less than 1% of all testicular tumors, and they are more common in older men, typically between the ages of 40 and 60. They can be either cystic or solid, and they may or may not produce hormones that can affect blood tests.
The symptoms of Sertoli-Leydig cell tumor can vary depending on the location and size of the tumor. Some common symptoms include:
* Pain in the testicle, scrotum, or lower abdomen
* Swelling or enlargement of the testicle
* Abnormalities in semen production, such as decreased volume or changes in consistency
* Discomfort or pain during ejaculation
* Enlargement of the epididymis (a tube that runs along the back of the testicle)
If you experience any of these symptoms, it is important to see a doctor for proper evaluation and diagnosis. A physical examination and imaging tests such as ultrasound or CT scan can help to identify the presence of a Sertoli-Leydig cell tumor. A biopsy may also be performed to confirm the diagnosis.
Treatment for Sertoli-Leydig cell tumors typically involves surgery to remove the affected testicle, followed by hormone therapy to reduce the levels of male hormones that can stimulate the growth of remaining testicular tissue. In some cases, radiation therapy may also be recommended to ensure complete removal of the tumor.
Overall, Sertoli-Leydig cell tumors are rare and relatively benign types of testicular cancer, but they can still cause significant symptoms and require proper medical attention for diagnosis and treatment.
Pancreatic adenocarcinoma is the most common type of malignant pancreatic neoplasm and accounts for approximately 85% of all pancreatic cancers. It originates in the glandular tissue of the pancreas and has a poor prognosis, with a five-year survival rate of less than 10%.
Pancreatic neuroendocrine tumors (PNETs) are less common but more treatable than pancreatic adenocarcinoma. These tumors originate in the hormone-producing cells of the pancreas and can produce excess hormones that cause a variety of symptoms, such as diabetes or high blood sugar. PNETs are classified into two main types: functional and non-functional. Functional PNETs produce excess hormones and are more aggressive than non-functional tumors.
Other rare types of pancreatic neoplasms include acinar cell carcinoma, ampullary cancer, and oncocytic pancreatic neuroendocrine tumors. These tumors are less common than pancreatic adenocarcinoma and PNETs but can be equally aggressive and difficult to treat.
The symptoms of pancreatic neoplasms vary depending on the type and location of the tumor, but they often include abdominal pain, weight loss, jaundice, and fatigue. Diagnosis is typically made through a combination of imaging tests such as CT scans, endoscopic ultrasound, and biopsy. Treatment options for pancreatic neoplasms depend on the type and stage of the tumor but may include surgery, chemotherapy, radiation therapy, or a combination of these.
Prognosis for patients with pancreatic neoplasms is generally poor, especially for those with advanced stages of disease. However, early detection and treatment can improve survival rates. Research into the causes and mechanisms of pancreatic neoplasms is ongoing, with a focus on developing new and more effective treatments for these devastating diseases.
The tumor typically grows slowly, and symptoms may include painless lumps or swelling in the neck, face, or jaw. Treatment usually involves surgical removal of the tumor, and the prognosis is generally good, with a low risk of recurrence. However, some cases may be difficult to diagnose correctly, as the symptoms can be similar to those of other conditions, such as a thyroid nodule or a salivary gland tumor.
The exact cause of adenolymphoma is not known, but it is believed to arise from genetic mutations that occur during embryonic development. The condition usually affects adults between 30 and 50 years old, with a slight predilection for women.
Adenolymphoma is a rare tumor, and there is limited research on its incidence and prevalence. However, it is estimated that approximately 1 in 1 million people develop this condition each year. The diagnosis of adenolymphoma can be challenging, and the tumor may be mistaken for other benign or malignant conditions. Therefore, proper clinical evaluation and imaging studies are essential to make an accurate diagnosis and determine the appropriate treatment.
Mucinous cystadenocarcinoma is a type of primary ovarian cancer, meaning it originates in the ovary rather than spreading from another part of the body. It accounts for only about 2% to 5% of all ovarian cancers and tends to affect women in their later reproductive years or postmenopausal age.
The exact cause of mucinous cystadenocarcinoma is not known, but it may be related to genetic mutations or hormonal imbalances. Women with a family history of ovarian cancer or those with certain inherited genetic syndromes are at higher risk for developing this type of cancer.
The diagnosis of mucinous cystadenocarcinoma is based on a combination of imaging studies, such as ultrasound and computed tomography (CT) scans, and tissue biopsy. Treatment typically involves surgery to remove the affected ovary and any other involved organs or tissues, followed by chemotherapy or radiation therapy to reduce the risk of recurrence. Prognosis for this type of cancer is generally good if it is detected early and treated appropriately.
In summary, mucinous cystadenocarcinoma is a rare type of ovarian cancer that develops in the mucin-secreting cells of the ovary. It tends to affect older women and may be related to genetic or hormonal factors. Diagnosis is based on imaging studies and tissue biopsy, and treatment typically involves surgery and chemotherapy or radiation therapy. Prognosis is generally good if caught early.
There are several types of cecal diseases that can affect humans, including:
1. Cecal volvulus: This is a condition where the cecum becomes twisted or looped, leading to abdominal pain, nausea, and vomiting.
2. Cecal cancer: This is a type of colon cancer that originates in the cecum. It is rare and often symptomless in its early stages.
3. Cecal diverticulosis: This is a condition where small pouches or sacs form in the wall of the cecum, leading to abdominal pain and other symptoms.
4. Cecal inflammatory polyps: These are growths that occur in the lining of the cecum and can cause bleeding, pain, and other symptoms.
5. Cecal strictures: This is a condition where the cecum becomes narrowed or constricted, leading to abdominal pain, nausea, and vomiting.
6. Cecal ulcers: These are open sores that occur in the lining of the cecum, often caused by inflammation or infection.
7. Cecal tuberculosis: This is a type of tuberculosis that affects the cecum, often causing symptoms such as abdominal pain, fever, and weight loss.
8. Cecal abscesses: These are pockets of pus that form in the cecum, often caused by bacterial infection.
9. Cecal fistulae: These are abnormal connections between the cecum and other organs or structures in the abdominal cavity.
These are just a few examples of cecal diseases that can affect humans. It's important to note that many of these conditions are rare and may not be well-known to the general public. If you suspect you have a cecal disease, it is important to seek medical attention as soon as possible for proper diagnosis and treatment.
Spermatoceles are usually small and do not cause any symptoms. However, if they become large enough, they can cause discomfort or pain in the scrotum or testicles. They may also affect fertility by blocking the flow of sperm from the epididymis into the vas deferens.
Spermatocele is a type of hydrocele, which means that it is caused by an accumulation of fluid within a closed sac-like structure. Hydroceles can occur in other parts of the body, such as the groin or abdomen, but spermatocele specifically affects the epididymis.
The exact cause of spermatocele is not known, but it may be related to inflammation or blockage of the epididymis. It can also occur as a result of surgery or trauma to the groin area.
Diagnosis of spermatocele is usually made through ultrasound or scrotal imaging. Treatment for spermatocele may involve draining the fluid from the cyst, or in some cases, surgical removal of the affected portion of the epididymis.
In conclusion, a spermatocele is a benign cyst that forms in the epididymis and can cause discomfort, pain, or fertility issues in men. It is important to seek medical attention if symptoms persist or worsen over time.
Types of Endocrine Gland Neoplasms:
1. Thyroid Cancer: A malignant tumor that develops in the thyroid gland, which can cause an overproduction or underproduction of thyroid hormones.
2. Adrenal Cancer: A malignant tumor that develops in the adrenal glands, which can produce excess hormones that can cause various symptoms.
3. Pancreatic Neuroendocrine Tumors (PNETs): Tumors that develop in the pancreas and produce excess hormones that can cause a variety of symptoms.
4. Parathyroid Cancer: A malignant tumor that develops in the parathyroid glands, which regulate calcium levels in the blood.
5. Pituitary Tumors: Benign or malignant growths that develop in the pituitary gland, which can affect hormone production and cause various symptoms.
Causes and Risk Factors:
1. Genetic mutations
2. Exposure to certain chemicals or radiation
3. Family history of endocrine disorders
4. Previous radiation therapy
5. Age, with most cases occurring in people over the age of 40
Symptoms:
1. Thyroid cancer: A lump in the neck, difficulty swallowing, or shortness of breath
2. Adrenal cancer: High blood pressure, weight gain, or muscle weakness
3. PNETs: Diarrhea, abdominal pain, or weight loss
4. Parathyroid cancer: High calcium levels in the blood, kidney stones, or osteoporosis
5. Pituitary tumors: Headaches, vision changes, or hormonal imbalances
Treatment options for endocrine cancers depend on the specific type of cancer, its location, and its stage. Treatment may include surgery, radiation therapy, chemotherapy, or a combination of these. In some cases, hormone replacement therapy may also be necessary.
Prognosis:
The prognosis for endocrine cancers varies by type. In general, the earlier the cancer is diagnosed and treated, the better the prognosis. Thyroid cancer has a good prognosis, with a 5-year survival rate of around 97%. Adrenal cancer has a lower survival rate of around 60%, while PNETs have a poorer prognosis, with a 5-year survival rate of around 30%. Parathyroid cancer and pituitary tumors have better prognoses, with 5-year survival rates of around 90% and 80%, respectively.
Prevention:
There is no guaranteed way to prevent endocrine cancers, but certain measures may help reduce the risk. These include:
* Reducing exposure to radiation: Minimizing exposure to radiation, such as from CT scans, can help reduce the risk of developing thyroid cancer.
* Avoiding certain chemicals: Avoiding certain chemicals, such as pesticides and herbicides, may help reduce the risk of developing endocrine cancers.
* Maintaining a healthy lifestyle: Maintaining a healthy lifestyle, including eating a balanced diet and exercising regularly, may help reduce the risk of developing endocrine cancers.
* Early detection: Early detection and treatment of endocrine cancers can improve prognosis. Regular check-ups with an endocrinologist can help identify any abnormalities early on.
In conclusion, endocrine cancers are a diverse group of tumors that can affect various parts of the endocrine system. Early detection and treatment are crucial for improving prognosis, and prevention measures such as reducing exposure to radiation and maintaining a healthy lifestyle may also be helpful. It is important to seek medical attention if any symptoms persist or worsen over time.
Benign ovarian neoplasms include:
1. Serous cystadenoma: A fluid-filled sac that develops on the surface of the ovary.
2. Mucinous cystadenoma: A tumor that is filled with mucin, a type of protein.
3. Endometrioid tumors: Tumors that are similar to endometrial tissue (the lining of the uterus).
4. Theca cell tumors: Tumors that develop in the supportive tissue of the ovary called theca cells.
Malignant ovarian neoplasms include:
1. Epithelial ovarian cancer (EOC): The most common type of ovarian cancer, which arises from the surface epithelium of the ovary.
2. Germ cell tumors: Tumors that develop from germ cells, which are the cells that give rise to eggs.
3. Stromal sarcomas: Tumors that develop in the supportive tissue of the ovary.
Ovarian neoplasms can cause symptoms such as pelvic pain, abnormal bleeding, and abdominal swelling. They can also be detected through pelvic examination, imaging tests such as ultrasound and CT scan, and biopsy. Treatment options for ovarian neoplasms depend on the type, stage, and location of the tumor, and may include surgery, chemotherapy, and radiation therapy.
healthline.com › health › aspirin
Definition of Aspermia: Aspermia is a condition where a man does not produce any semen during ejaculation. This can be due to various causes such as blockage in the reproductive tract, hormonal imbalance, or certain medical conditions like diabetes or hypogonadism. Aspermia can make it difficult or impossible for a man to father a child naturally.
Aspermia is also known as:
* Dry ejaculation
* Hypospermia
* Oligospermia
References:
* American Urological Association. (2019). Aspermia. Retrieved from
* MedlinePlus. (2020). Aspermia. Retrieved from
Pseudomyxoma peritonei can occur in anyone, but it is most common in women between the ages of 20 and 50. The exact cause of this condition is not known, but it may be linked to genetic changes or previous abdominal surgery.
Symptoms of pseudomyxoma peritonei can include abdominal pain, bloating, nausea, and vomiting. These symptoms are often persistent and can worsen over time. In some cases, the tumors can become large enough to compress nearby organs, leading to additional complications such as bowel obstruction or kidney damage.
If you suspect that you may have pseudomyxoma peritonei, your doctor will begin by performing a physical exam and taking a medical history. Imaging tests such as CT scans or PET scans may also be ordered to help visualize the tumors and determine their extent. A diagnosis of pseudomyxoma peritonei is typically made based on the presence of mucin-secreting tumors on the peritoneum, along with other characteristic features such as the absence of a primary tumor site.
Treatment for pseudomyxoma peritonei usually involves surgery to remove as many of the tumors as possible. In some cases, chemotherapy or radiation therapy may also be recommended to help shrink the tumors before surgery or to kill any remaining cancer cells after surgery.
The prognosis for pseudomyxoma peritonei is generally good if the condition is detected and treated early. However, if the tumors are allowed to grow and spread, the outlook can be poorer. In rare cases, the tumors may recur even after successful treatment.
1. Parotid gland tumors: These are the most common type of salivary gland tumor and can be benign or malignant.
2. Submandibular gland tumors: These are less common than parotid gland tumors but can also be benign or malignant.
3. Sublingual gland tumors: These are rare and usually benign.
4. Warthin's tumor: This is a type of benign tumor that affects the parotid gland.
5. Mucoepidermoid carcinoma: This is a type of malignant tumor that can occur in any of the major salivary glands.
6. Acinic cell carcinoma: This is a rare type of malignant tumor that usually occurs in the parotid gland.
7. Adenoid cystic carcinoma: This is a slow-growing malignant tumor that can occur in any of the major salivary glands.
8. Metastatic tumors: These are tumors that have spread to the salivary glands from another part of the body.
Salivary gland neoplasms can cause a variety of symptoms, including painless lumps or swelling in the neck or face, difficulty swallowing, and numbness or weakness in the face. Treatment options depend on the type and stage of the tumor and may include surgery, radiation therapy, and/or chemotherapy.
In conclusion, salivary gland neoplasms are a diverse group of cancers that affect the salivary glands, and it's important to be aware of the different types, symptoms, and treatment options in order to provide effective care for patients with these tumors.
1. Pancreatic mucinous cysts: These are the most common type of pancreatic cyst and are usually benign (non-cancerous). They can range in size from a few millimeters to several centimeters and may contain mucin, a type of protein.
2. Pancreatic pseudocysts: These are fluid-filled sacs that develop after pancreatitis, an inflammation of the pancreas. Pseudocysts are usually more solid than mucinous cysts and can be filled with pancreatic tissue, blood, and other debris.
3. Intraductal papillary mucinous neoplasms (IPMNs): These are precancerous growths that develop in the pancreatic ducts and can progress to pancreatic cancer if left untreated.
4. Other rare types of pancreatic cysts include serous cystic neoplasms, clear cell cysts, and oncocytic cysts.
Pancreatic cysts may not cause any symptoms in their early stages, but as they grow, they can press on nearby organs and cause pain, nausea, vomiting, and other digestive problems. Large cysts can also block the pancreatic ducts, leading to pancreatitis.
Diagnosis of pancreatic cysts typically involves imaging tests such as CT scans, MRI scans, or endoscopic ultrasound. Fine-needle aspiration (FNA) biopsy may also be performed to collect a sample of the cyst fluid for further examination.
Treatment of pancreatic cysts depends on their type, size, and location. Small, benign cysts may not require treatment and can be monitored with regular imaging tests. Larger cysts may need to be drained or removed surgically, especially if they are causing symptoms or increasing in size.
It is essential for individuals with a history of pancreatic cysts to follow up regularly with their healthcare provider to monitor for any changes in the cysts and to ensure early detection of any potential cancerous changes.
Multiple primary neoplasms can arise in different organs or tissues throughout the body, such as the breast, colon, prostate, lung, or skin. Each tumor is considered a separate entity, with its own unique characteristics, including size, location, and aggressiveness. Treatment for multiple primary neoplasms typically involves surgery, chemotherapy, radiation therapy, or a combination of these modalities.
The diagnosis of multiple primary neoplasms can be challenging due to the overlapping symptoms and radiological findings between the different tumors. Therefore, it is essential to have a thorough clinical evaluation and diagnostic workup to rule out other possible causes of the symptoms and confirm the presence of multiple primary neoplasms.
Multiple primary neoplasms are more common than previously thought, with an estimated prevalence of 2% to 5% in some populations. The prognosis for patients with multiple primary neoplasms varies depending on the location, size, and aggressiveness of each tumor, as well as the patient's overall health status.
It is important to note that multiple primary neoplasms are not the same as metastatic cancer, in which a single primary tumor spreads to other parts of the body. Multiple primary neoplasms are distinct tumors that arise independently from different primary sites within the body.
Retroperitoneal neoplasms can occur in various locations, including the kidney, adrenal gland, pancreas, liver, spleen, and small intestine. These tumors can cause a variety of symptoms, such as abdominal pain, weight loss, fever, and difficulty urinating or passing stool.
The diagnosis of retroperitoneal neoplasms is based on a combination of imaging studies, such as computed tomography (CT) scans, magnetic resonance imaging (MRI), and positron emission tomography (PET) scans, and a biopsy, which involves removing a small sample of tissue from the suspected tumor and examining it under a microscope.
Treatment options for retroperitoneal neoplasms depend on the type, size, location, and stage of the tumor, as well as the patient's overall health. Surgery is often the first line of treatment, and may involve removing the tumor and any affected surrounding tissue or organs. Radiation therapy and chemotherapy may also be used to shrink the tumor before surgery or to kill any remaining cancer cells after surgery.
Some common types of retroperitoneal neoplasms include:
1. Renal cell carcinoma (RCC): a type of kidney cancer that originates in the cells that line the renal tubules.
2. Adrenocortical carcinoma: a type of cancer that arises in the adrenal gland.
3. Pancreatic neuroendocrine tumors: tumors that arise in the pancreas and produce excess hormones.
4. Liver cancer (hepatocellular carcinoma): a type of cancer that originates in the liver cells.
5. Gastrointestinal stromal tumors (GISTs): tumors that arise in the digestive system, usually in the stomach or small intestine.
6. Soft tissue sarcomas: tumors that arise in the soft tissues of the body, such as the muscles, fat, and connective tissue.
7. Retroperitoneal fibrosis: a condition where the tissue in the retroperitoneum becomes scarred and thickened.
8. Metastatic tumors: tumors that have spread to the retroperitoneum from another part of the body, such as the lung, breast, or colon.
It is important to note that this is not an exhaustive list and there may be other types of retroperitoneal neoplasms not mentioned here. If you suspect you may have a retroperitoneal neoplasm, it is important to consult with a qualified medical professional for proper diagnosis and treatment.
Pseudocysts are typically caused by inflammation or injury to the pancreas, which can lead to the formation of fluid-filled spaces within the organ. These spaces are not surrounded by a layer of epithelial cells, as is the case with true pancreatic cysts.
Pancreatic pseudocysts may not cause any symptoms and may be discovered incidentally during diagnostic imaging studies. However, they can also cause abdominal pain, nausea, vomiting, fever, and other symptoms depending on their size and location.
Treatment of pancreatic pseudocysts is usually conservative, involving observation, fluid drainage, and management of any underlying causes such as infection or inflammation. Surgical intervention may be necessary if the pseudocyst becomes infected, bleeds, or causes other complications.
It's important to note that while pancreatic pseudocysts are generally less serious than true cysts, they can still cause significant morbidity and mortality if left untreated or if there is a delay in diagnosis and treatment. Therefore, it's important for healthcare providers to be aware of the differences between pseudocysts and true pancreatic cysts, as well as the appropriate diagnostic and treatment approaches for each condition.
Types of Ovarian Cysts:
1. Functional cysts: These cysts form during the menstrual cycle and are usually small and disappear on their own within a few days or weeks.
2. Follicular cysts: These cysts form when a follicle (a tiny sac containing an egg) does not release an egg and instead fills with fluid.
3. Corpus luteum cysts: These cysts form when the corpus luteum (the sac that holds an egg after it's released from the ovary) does not dissolve after pregnancy or does not produce hormones properly.
4. Endometrioid cysts: These cysts are formed when endometrial tissue (tissue that lines the uterus) grows outside of the uterus and forms a cyst.
5. Cystadenomas: These cysts are benign tumors that grow on the surface of an ovary or inside an ovary. They can be filled with a clear liquid or a thick, sticky substance.
6. Dermoid cysts: These cysts are formed when cells from the skin or other organs grow inside an ovary. They can contain hair follicles, sweat glands, and other tissues.
Symptoms of Ovarian Cysts:
1. Pelvic pain or cramping
2. Bloating or discomfort in the abdomen
3. Heavy or irregular menstrual bleeding
4. Pain during sex
5. Frequent urination or difficulty emptying the bladder
6. Abnormal vaginal bleeding or spotting
Diagnosis and Treatment of Ovarian Cysts:
1. Pelvic examination: A doctor will check for any abnormalities in the reproductive organs.
2. Ultrasound: An ultrasound can help identify the presence of a cyst and determine its size, location, and composition.
3. Blood tests: Blood tests can be used to check hormone levels and rule out other conditions that may cause similar symptoms.
4. Laparoscopy: A laparoscope (a thin tube with a camera and light) is inserted through a small incision in the abdomen to visualize the ovaries and remove any cysts.
5. Surgical removal of cysts: Cysts can be removed by surgery, either through laparoscopy or open surgery.
6. Medications: Hormonal medications may be prescribed to shrink the cyst and alleviate symptoms.
It is important to note that not all ovarian cysts cause symptoms, and some may go away on their own without treatment. However, if you experience any of the symptoms mentioned above or have concerns about an ovarian cyst, it is essential to consult a healthcare provider for proper diagnosis and treatment.
Exocrine disorders affect the pancreas' ability to produce digestive enzymes, leading to symptoms such as abdominal pain, diarrhea, and malnutrition. The most common exocrine disorder is chronic pancreatitis, which is inflammation of the pancreas that can lead to permanent damage and scarring. Other exocrine disorders include acute pancreatitis, pancreatic insufficiency, and pancreatic cancer.
Endocrine disorders affect the pancreas' ability to produce hormones, leading to symptoms such as diabetes, hypoglycemia, and Cushing's syndrome. The most common endocrine disorder is diabetes mellitus, which is caused by a deficiency of insulin production or insulin resistance. Other endocrine disorders include hyperglycemia, hypoglycemia, and pancreatic polypeptide-secreting tumors.
Pancreatic diseases can be caused by a variety of factors, including genetics, lifestyle choices, and certain medical conditions. Treatment options for pancreatic diseases vary depending on the underlying cause and severity of the condition, and may include medications, surgery, or lifestyle changes. Early diagnosis and treatment are critical for improving outcomes in patients with pancreatic diseases.
Some of the most common types of pancreatic diseases include:
1. Diabetes mellitus: a group of metabolic disorders characterized by high blood sugar levels.
2. Chronic pancreatitis: inflammation of the pancreas that can lead to permanent damage and scarring.
3. Acute pancreatitis: sudden and severe inflammation of the pancreas, often caused by gallstones or excessive alcohol consumption.
4. Pancreatic cancer: a malignancy that can arise in the pancreas and spread to other parts of the body.
5. Pancreatic neuroendocrine tumors (PNETs): tumors that arise in the hormone-producing cells of the pancreas and can produce excessive amounts of hormones, leading to a variety of symptoms.
6. Pancreatic polypeptide-secreting tumors: rare tumors that produce excessive amounts of pancreatic polypeptide, leading to hypoglycemia and other symptoms.
7. Glucagonoma: a rare tumor that produces excessive amounts of glucagon, leading to high blood sugar levels and other symptoms.
8. Insulinoma: a rare tumor that produces excessive amounts of insulin, leading to low blood sugar levels and other symptoms.
9. Multiple endocrine neoplasia (MEN) type 1: an inherited disorder characterized by multiple endocrine tumors, including those in the pancreas.
10. Familial pancreatico-ductal adenocarcinoma (FPDA): an inherited disorder characterized by a high risk of developing pancreatic cancer.
These are just some of the possible causes of pancreatic disease, and there may be others not listed here. It is important to consult with a healthcare professional for an accurate diagnosis and appropriate treatment.
The term "serous" refers to the fact that the tumor produces a fluid-filled cyst, which typically contains a clear, serous (watery) liquid. The cancer cells are typically found in the outer layer of the ovary, near the surface of the organ.
Cystadenocarcinoma, serous is the most common type of ovarian cancer, accounting for about 50-60% of all cases. It is often diagnosed at an advanced stage, as it can be difficult to detect in its early stages. Symptoms may include abdominal pain, bloating, and changes in bowel or bladder habits.
Treatment for cystadenocarcinoma, serous usually involves a combination of surgery and chemotherapy. Surgery may involve removing the uterus, ovaries, and other affected tissues, followed by chemotherapy to kill any remaining cancer cells. In some cases, radiation therapy may also be used.
Prognosis for cystadenocarcinoma, serous varies depending on the stage of the cancer at diagnosis. Women with early-stage disease have a good prognosis, while those with advanced-stage disease have a poorer outlook. However, overall survival rates have improved in recent years due to advances in treatment and screening.
In summary, cystadenocarcinoma, serous is a type of ovarian cancer that originates in the lining of the ovary and grows slowly over time. It can be difficult to detect in its early stages, but treatment typically involves surgery and chemotherapy. Prognosis varies depending on the stage of the cancer at diagnosis.
Examples of 'Adenocarcinoma, Mucinous' in medical literature:
* The patient was diagnosed with adenocarcinoma, mucinous type, in their colon after undergoing a colonoscopy and biopsy. (From the Journal of Clinical Oncology)
* The patient had a history of adenocarcinoma, mucinous type, in their breast and was being monitored for potential recurrence. (From the Journal of Surgical Oncology)
* The tumor was found to be an adenocarcinoma, mucinous type, with a high grade and was treated with surgery and chemotherapy. (From the Journal of Gastrointestinal Oncology)
Synonyms for 'Adenocarcinoma, Mucinous' include:
* Mucinous adenocarcinoma
* Colon adenocarcinoma, mucinous type
* Rectal adenocarcinoma, mucinous type
* Adenocarcinoma of the colon and rectum, mucinous type.
Cystadenoma
Ovarian cystadenoma
Serous cystadenoma
Mucinous cystadenoma
Pancreatic mucinous cystadenoma
Pancreatic serous cystadenoma
Ovarian serous cystadenoma
Ovary
Mucinous cystadenocarcinoma of the lung
Papillary serous cystadenocarcinoma
Surgical Outcomes Analysis and Research
Adenoma
Cystadenocarcinoma
Pancreatic mucinous cystic neoplasm
Appendix cancer
Hereditary leiomyomatosis and renal cell cancer syndrome
Aldred Scott Warthin
Intraductal papillary mucinous neoplasm
Ovarian cyst
Hidrocystoma
International Classification of Diseases for Oncology
Warthin's tumor
Endolymphatic sac tumor
Solid pseudopapillary tumour
Pseudomyxoma peritonei
List of skin conditions
Forme fruste
Serous cystadenocarcinoma
List of MeSH codes (C04)
Salivary gland tumour
Pancreatic Serous Cystadenoma Imaging: Practice Essentials, Computed Tomography, Magnetic Resonance Imaging
Laparoscopic Transgastric Cyst Gastrostomy for an Unresectable Mucinous Cyst Adenoma of the Pancreas - SAGES Abstract Archives
Surgical treatment for giant multilocular prostatic cystadenoma including multiple organ compression symptoms: A case report<...
Giant mucinous cystadenoma: a case report. | J Med Case Rep;13(1): 181, 2019 Jun 14. | MEDLINE | BVS CLAP/SMR-OPAS/OMS
STOCK IMAGE,
,
518 Ovarian mucinous cystadenoma Oleksandr Chyrkov6 4388,
01BA9EXR
...
Radiology Quiz 72334 | Radiopaedia.org
Hepatobiliary Tumors | Moffitt
Amelia M. Wodzinski, MSN, CRNP, AOCNP profile | PennMedicine.org
Related Articles - Annals Singapore
Department of Mathematics, Scott Christian College, Nagercoil, India - Articles - Scientific Research Publishing
IndexCat
Carney complex - About the Disease - Genetic and Rare Diseases Information Center
Ovarian cysts: Warning signs, causes, types, treatment and all you want to know | Health - Hindustan Times
NIH Clinical Center Search the Studies: Study Number, Study Title
Pancreas: Neuroendocrine Tumors (pnet) Imaging Pearls - Educational Tools | CT Scanning | CT Imaging | CT Scan Protocols -...
KoreaMed
Buy authentic Prednisone now at the lowest prices. Prednisone Capsules For Sale
ICD-10 Code for Person boarding or alighting a pick-up truck or van injured in collision with pedestrian or animal- V50.4-...
Echinococcus vogeli in Immigrant from Suriname to the Netherlands - Volume 21, Number 3-March 2015 - Emerging Infectious...
Combined Deletion of Vhl and Kif3a Accelerates Renal Cyst Fo... : Journal of the American Society of Nephrology
DailyMed - MIRTAZAPINE tablet, film coated
MeSH Browser
Mucinous | Mucinous Medical
MeSH Browser
Biliary cystadenoma6
- 2. Malignant transformation of biliary cystadenoma: a difficult diagnosis. (nih.gov)
- 4. Giant biliary cystadenoma complicated with polycystic liver: a case report. (nih.gov)
- 10. [Biliary cystadenoma and cystadenocarcinoma]. (nih.gov)
- 12. Biliary cystadenoma and other complicated cystic lesions of the liver: diagnostic and therapeutic challenges. (nih.gov)
- Abdominal ultrasonography and subsequent computed tomography revealed a lesion with solid and liquid components in liver segment 4, considered consistent with a biliary cystadenoma or an echinococcal cyst. (cdc.gov)
- Biliary cystadenoma is a rare cystic tumor of the liver. (heighpubs.org)
Cysts1
- Lastly some pathological tumours can present as ovarian cysts like dermoids and serous cystadenoma etc. (hindustantimes.com)
Serous11
- The 2 most common cystic neoplasms of the pancreas are serous cystadenoma and mucinous cystic neoplasm. (medscape.com)
- The important point to remember is that serous cystadenoma is benign, whereas the biologic behavior of the mucinous cystic neoplasm and the IPMT ranges from benign to malignant. (medscape.com)
- In a study of 2622 patients with serous cystadenoma, 74% were women, with a mean age of 58 years. (medscape.com)
- To avoid serious complications of pancreatic surgery, serous cystadenoma should be diagnosed accurately at the preoperative level. (medscape.com)
- Findings from plain radiography and upper GI series are nondiagnostic, except the finding of a classic sunburst central calcification, which is suggestive of a serous cystadenoma. (medscape.com)
- Serous cystadenoma on a contrast-enhanced CT scan. (medscape.com)
- MRIs of serous cystadenoma. (medscape.com)
- Sonogram of serous cystadenoma. (medscape.com)
- A serous cystadenoma should be diagnosed with caution unless the lesion has all of the typical findings. (medscape.com)
- Serous cystadenoma (52.7%) was the commonest benign tumor followed by Mucinous Modi D, Rathod GB, Delwadia KN, Goswami HM. (who.int)
- Serous cystadenoma was the most common ovarian tumor overall as well as the most common benign tumor, whereas serous cystadenocarcinoma was the most common ovarian malignancy. (who.int)
Morphologic1
- 17. Hepatobiliary cystadenoma exhibiting morphologic changes from simple hepatic cyst shown by 11-year follow up imagings. (nih.gov)
Tumors1
- Mucinous Cystadenoma- Rare Type of Ovarian Tumor There are different types of ovarian tumors affecting the human body. (mucinous.org)
Multilocular1
- Multilocular mucinous cystadenoma with foci showing borderline features. (radiopaedia.org)
Cystadenocarcinoma1
- 16. Hepatobiliary cystadenoma and cystadenocarcinoma: a single center experience. (nih.gov)
Diagnosis1
- Histologically, the tumor cystic wall was composed of epithelial cells showed positive immunohistochemical staining of the epithelial prostatic specific antigen, the final pathological diagnosis was prostatic cystadenoma (Rinsho Hinyokika 75: 157-16 1 2021). (elsevier.com)
Giant2
- Giant mucinous cystadenoma: a case report. (bvsalud.org)
- CASE PRESENTATION We present a case of a 48-year-old black African woman with a giant mucinous cystadenoma who presented to a tertiary hospital with massive abdominal distention 5 years after being referred from a district hospital for the same problem. (bvsalud.org)
Mucinous3
- The 2 most common cystic neoplasms of the pancreas are serous cystadenoma and mucinous cystic neoplasm. (medscape.com)
- The important point to remember is that serous cystadenoma is benign, whereas the biologic behavior of the mucinous cystic neoplasm and the IPMT ranges from benign to malignant. (medscape.com)
- 3. Hepatobiliary Mucinous Cystic Neoplasms With Ovarian Type Stroma (So-Called "Hepatobiliary Cystadenoma/Cystadenocarcinoma"): Clinicopathologic Analysis of 36 Cases Illustrates Rarity of Carcinomatous Change. (nih.gov)
Pancreatic1
- To avoid serious complications of pancreatic surgery, serous cystadenoma should be diagnosed accurately at the preoperative level. (medscape.com)
Pancreas1
- Cystadenoma of the pancreas. (nih.gov)